Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CAPR NASDAQ:CRSP NASDAQ:LEGN NASDAQ:TVTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$23.21$28.87$4.30▼$40.37$1.34B0.421.51 million shs1.64 million shsCRSPCRISPR Therapeutics$60.08$52.78$44.12▼$78.48$5.79B1.711.62 million shs2.93 million shsLEGNLegend Biotech$29.91$29.29$16.24▼$45.30$5.56B0.342.53 million shs1.41 million shsTVTXTravere Therapeutics$56.900.0%$47.98$14.44▼$60.10$5.29B1.12.34 million shs1.70 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-12.22%-16.03%-27.72%+131.64%CRSPCRISPR Therapeutics0.00%+9.40%+15.36%+21.35%+16.28%LEGNLegend Biotech0.00%+4.25%-16.87%+56.27%-16.71%TVTXTravere Therapeutics0.00%-3.31%+25.88%+86.93%+283.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCAPRCapricor Therapeutics$23.21$28.87$4.30▼$40.37$1.34B0.421.51 million shs1.64 million shsCRSPCRISPR Therapeutics$60.08$52.78$44.12▼$78.48$5.79B1.711.62 million shs2.93 million shsLEGNLegend Biotech$29.91$29.29$16.24▼$45.30$5.56B0.342.53 million shs1.41 million shsTVTXTravere Therapeutics$56.900.0%$47.98$14.44▼$60.10$5.29B1.12.34 million shs1.70 million shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCAPRCapricor Therapeutics0.00%-12.22%-16.03%-27.72%+131.64%CRSPCRISPR Therapeutics0.00%+9.40%+15.36%+21.35%+16.28%LEGNLegend Biotech0.00%+4.25%-16.87%+56.27%-16.71%TVTXTravere Therapeutics0.00%-3.31%+25.88%+86.93%+283.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCAPRCapricor Therapeutics 2.90Moderate Buy$53.67131.22% UpsideCRSPCRISPR Therapeutics 2.58Moderate Buy$67.7812.81% UpsideLEGNLegend Biotech 2.67Moderate Buy$60.23101.37% UpsideTVTXTravere Therapeutics 2.69Moderate Buy$52.08-8.47% DownsideCurrent Analyst Ratings BreakdownLatest CAPR, LEGN, CRSP, and TVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026TVTXTravere Therapeutics GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$56.00 ➝ $65.006/25/2026CAPRCapricor Therapeutics LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/24/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/23/2026TVTXTravere Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/22/2026TVTXTravere Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$55.00 ➝ $61.006/15/2026CAPRCapricor Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/15/2026TVTXTravere Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$62.00 ➝ $70.006/12/2026CRSPCRISPR Therapeutics UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$80.006/12/2026TVTXTravere Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$50.00 ➝ $65.006/11/2026CRSPCRISPR Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetEqual Weight$60.006/3/2026LEGNLegend Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCAPRCapricor Therapeutics$22.27M60.35N/AN/A$5.53 per share4.20CRSPCRISPR Therapeutics$3.51M1,650.92N/AN/A$20.17 per share2.98LEGNLegend Biotech$1.03B5.40N/AN/A$5.43 per share5.51TVTXTravere Therapeutics$490.73M10.78$0.36 per share157.18$1.28 per share44.45Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCAPRCapricor Therapeutics-$105.04M-$2.32N/AN/AN/AN/A-59.27%-48.65%8/11/2026 (Estimated)CRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%8/3/2026 (Estimated)LEGNLegend Biotech-$296.80M-$0.68N/A18.02N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)TVTXTravere Therapeutics-$25.55M-$0.23N/A43.11N/A-4.00%-26.16%-3.71%8/5/2026 (Estimated)Latest CAPR, LEGN, CRSP, and TVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026LEGNLegend Biotech-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million5/12/2026Q1 2026CAPRCapricor Therapeutics-$0.55-$0.59-$0.04-$0.59$40.00 millionN/A5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million5/4/2026Q1 2026TVTXTravere Therapeutics-$0.2420$0.05+$0.2920-$0.40$136.23 million$127.20 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCAPRCapricor TherapeuticsN/AN/AN/AN/AN/ACRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ATVTXTravere TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCAPRCapricor TherapeuticsN/A8.428.42CRSPCRISPR Therapeutics0.3217.9717.96LEGNLegend BiotechN/A2.132.05TVTXTravere Therapeutics3.163.133.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCAPRCapricor Therapeutics21.68%CRSPCRISPR Therapeutics69.20%LEGNLegend Biotech70.89%TVTXTravere TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCAPRCapricor Therapeutics9.20%CRSPCRISPR Therapeutics4.30%LEGNLegend Biotech0.02%TVTXTravere Therapeutics4.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCAPRCapricor Therapeutics10157.91 million52.58 millionOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableLEGNLegend Biotech2,965185.74 million185.70 millionOptionableTVTXTravere Therapeutics46092.99 million88.86 millionOptionableCAPR, LEGN, CRSP, and TVTX HeadlinesRecent News About These CompaniesAssenagon Asset Management S.A. Decreases Stake in Travere Therapeutics, Inc. $TVTXJuly 4 at 3:20 AM | marketbeat.comTravere Therapeutics: Filspari Is Becoming A Rare Kidney Disease PlatformJuly 3 at 5:00 AM | seekingalpha.comSG Americas Securities LLC Increases Stock Holdings in Travere Therapeutics, Inc. $TVTXJuly 3 at 4:23 AM | marketbeat.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by BrokeragesJuly 3 at 2:29 AM | americanbankingnews.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 3 at 2:28 AM | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Sets New 52-Week High After Analyst UpgradeJune 22, 2026 | marketbeat.comWedbush Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock PriceJune 22, 2026 | marketbeat.comPerceptive Advisors LLC Has $163.47 Million Stock Holdings in Travere Therapeutics, Inc. $TVTXJune 18, 2026 | marketbeat.comElmind Capital LP Invests $4.20 Million in Travere Therapeutics, Inc. $TVTXJune 18, 2026 | marketbeat.comTravere Therapeutics, Inc. $TVTX Holdings Cut by Eversept Partners LPJune 18, 2026 | marketbeat.comArtia Global Partners LP Buys 39,800 Shares of Travere Therapeutics, Inc. $TVTXJune 18, 2026 | marketbeat.comTravere Therapeutics, Inc. $TVTX Shares Sold by Armistice Capital LLCJune 18, 2026 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Director Roy Baynes Sells 4,500 SharesJune 17, 2026 | insidertrades.comTravere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027June 16, 2026 | businesswire.comCitigroup Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock PriceJune 15, 2026 | marketbeat.comTravere Therapeutics (NASDAQ:TVTX) Sets New 12-Month High on Analyst UpgradeJune 15, 2026 | marketbeat.comFrazier Life Sciences Management L.P. Decreases Stake in Travere Therapeutics, Inc. $TVTXJune 14, 2026 | marketbeat.comIs Travere Therapeutics, Inc. (TVTX) A Good Stock To Buy Now?June 13, 2026 | insidermonkey.comEVEREST MED (01952.HK) Signs Exclusive License and Collaboration Agreement with Travere Therapeutics, Inc. (TVTX.US), to Receive USD112.5M Upfront PaymentJune 12, 2026 | aastocks.comATravere Therapeutics (TVTX) Gets a Buy from Wells FargoJune 12, 2026 | theglobeandmail.comTravere Therapeutics (NASDAQ:TVTX) Trading 7.6% Higher on Analyst UpgradeJune 12, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMission Control: Floating In SpaceX's Record-Breaking OrbitBy Jeffrey Neal Johnson | June 15, 2026SpaceX Rings the Bell and Shatters Every RecordBy Jeffrey Neal Johnson | June 12, 2026Gravity Check: Houston, SpaceX Has a Valuation ProblemBy Jeffrey Neal Johnson | June 16, 2026These 5 Companies Just Made a Massive Bet on ThemselvesBy Thomas Hughes | June 15, 2026Capri's Turnaround Is Taking Shape, But Is the Stock a Buy Yet?By Jennifer Ryan Woods | June 28, 2026CAPR, LEGN, CRSP, and TVTX Company DescriptionsCapricor Therapeutics NASDAQ:CAPR$23.21 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$23.04 -0.18 (-0.75%) As of 07/2/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. CRISPR Therapeutics NASDAQ:CRSP$60.08 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$59.63 -0.45 (-0.75%) As of 07/2/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Legend Biotech NASDAQ:LEGN$29.91 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$29.92 +0.00 (+0.02%) As of 07/2/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Travere Therapeutics NASDAQ:TVTX$56.90 -0.02 (-0.04%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$58.78 +1.88 (+3.30%) As of 07/2/2026 07:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Shorting the Grid: Bloom Energy’s $25B AI Power Play Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
